(Updated - November 13, 2020 6:01 AM EST)

(updating comment)Goldman Sachs analyst Graig Suvannavejh downgraded Kodiak Sciences Inc. (NASDAQ ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades

Kodiak Sciences Inc. (KOD) Reports Complete Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular DegenerationNovember 16, 2020 6:53 AM Kodiak Sciences to Present at Upcoming ConferencesNovember 12, 2020 4:12 PM Kodiak Sciences Inc. (KOD) PT Raised to $145 at BMO CapitalNovember 12, 2020 10:45 AM Kodiak Sciences Announces Presentation of KSI-301 Phase 1b Clinical Study Data Focused on Diabetic Macular Edema at American Academy of Ophthalmology (AAO) 2020 Virtual MeetingNovember 11, 2020 11:28 PM